Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 plus cisplatin/5-fluorouracil in recurrent/metastatic head and neck squamous cell carcinoma
CTR20190233Phase 2Completed
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sct200 in head and neck squamous cell carcinoma (HNSCC), sponsored by Shenzhou Cell Engineering Co., Ltd.. Started Mar 2019; status: completed.
02
Drugs
sct200
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20190233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190233.